Cashing Out Before the FDA Decision: Zealand Sells Rusfertide Revenue Rights for $100 Million

A blood disorder drug not yet approved for marketing has already generated immediately deployable funds for an early collaboration partner. Zealand Pharma has sold its economic interests related to rusfertide for $100 million, transferring potential future milestones and royalties to Royalty Pharma. At the time the transaction closed, the U.S. Food and Drug Administration (FDA) was conducting a priority review of the polycythemia vera candidate.

Under the agreement, Zealand receives $50 million at closing and another $50 million on the first anniversary of closing. The interests acquired by Royalty Pharma include regulatory and commercial milestones, as well as a 1% royalty on potential global net sales of rusfertide. If annual sales exceed $1.5 billion, Zealand retains a 0.25% royalty on the portion above that threshold, while the remaining 0.75% goes to Royalty Pharma.

This is not a transfer of drug ownership. Rusfertide is being developed by Protagonist Therapeutics, and Takeda Pharmaceutical leads the regulatory strategy and future filings under a global collaboration agreement; Zealand holds payment rights arising from an earlier collaboration. Zealand described the transaction as the monetization of a non-core royalty asset and said the proceeds will be invested in its metabolic disease-focused “Metabolic Frontier 2030” initiative. The company held DKK 14.457 billion in cash as of the end of June, making this transaction more akin to asset allocation than urgent fundraising.

Rusfertide is a hepcidin-mimetic peptide administered by weekly subcutaneous injection. By regulating iron homeostasis and red blood cell production, it helps control elevated hematocrit in patients with polycythemia vera. This chronic blood cancer increases blood viscosity, raising the risk of stroke, deep vein thrombosis, and pulmonary embolism; even with current treatment, some patients still require repeated phlebotomy to maintain hematocrit levels.

The FDA application is based primarily on the Phase 3 VERIFY study involving 293 participants, as well as long-term data from the Phase 2 REVIVE study and the THRIVE extension study. Takeda and Protagonist said rusfertide, in combination with standard therapy, improved hematocrit control, reduced the need for phlebotomy, and lowered fatigue and symptom burden. Overall tolerability through 52 weeks was acceptable, but common adverse events included injection-site reactions, anemia, and fatigue.

The FDA has granted the application priority review and is targeting a decision in the third quarter of 2026. This gives the transaction a clear risk exchange: Zealand gives up most of the potential future upside in return for certain funding, while Royalty Pharma is betting that the drug will pass review and generate substantial sales. Although the Phase 3 results support the application, regulatory approval, the scope of the label, commercial adoption, and long-term safety remain uncertain, and the $100 million price cannot be viewed as a guarantee of a successful launch.